ArticleProceedings of the National Academy of Sciences of the United States of America2021

A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.

Novalia Pishesha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.